A) Caelum Biosciences B) Synageva C) Proliferon D) Enobia Pharma
A) $1.08 billion B) $855 million C) $41 million D) $8.4 billion
A) Alexion Antibody Technologies B) Alexion Hematology C) Alexion Rare Disease D) Alexion Biopharma
A) June 2015 B) December 2011 C) September 2000 D) April 2018
A) Synageva treatment B) asfotase alfa C) Factor Xa inhibitor D) Proliferon serum
A) hypophosphatasia B) hematology disorders C) neurology disorders D) immune system disease
A) $8.4 billion B) $500 million C) $1.08 billion D) $41 million
A) Achillion Pharmaceuticals B) Synageva C) Syntimmune D) Wilson Therapeutics
A) $8.4 billion B) $930 million C) $855 million D) $1.2 billion
A) Portola Pharmaceuticals B) Proliferon C) Caelum Biosciences D) Wilson Therapeutics
A) $1.2 billion B) $500 million C) $930 million D) $855 million
A) Synageva B) Achillion Pharmaceuticals C) Syntimmune D) Enobia Pharma
A) $8.4 billion B) $1.08 billion C) $1.2 billion D) $41 million
A) Wilson Therapeutics B) Achillion Pharmaceuticals C) Caelum Biosciences D) Portola Pharmaceuticals
A) $855 million B) $500 million C) $1.2 billion D) $930 million
A) Expanding into hematology B) Acquiring asfotase alfa C) Boosting immune system disease pipeline D) Adding Factor Xa inhibitor
A) Synageva B) Enobia Pharma C) Syntimmune D) Portola Pharmaceuticals
A) Immune system disease pipeline B) Hematology, neurology, and critical care portfolio C) Development-stage biopharma holdings D) Rare disease offerings only
A) hypophosphatasia treatment B) Caelum therapeutics C) Factor Xa inhibitor reversal agent D) asfotase alfa
A) January 2020 B) October 2021 C) November 2018 D) July 2020
A) $855 million B) $500 million C) $930 million D) $41 million
A) Yale New Haven Hospital B) Honeywell C) AstraZeneca D) Moderna
A) Smithfield, Rhode Island B) New Haven, Connecticut C) Cheshire, Connecticut D) Boston, Massachusetts
A) Common cold medications B) Vaccine distribution C) Orphan drugs for rare diseases D) Oncology chemotherapy
A) Ultomiris B) Soliris C) Andexxa D) Strensiq
A) Cure bone fractures B) Treat liver failure C) Reduce cholesterol D) Stop life-threatening bleeding
A) 1992 B) 2000 C) 2010 D) 2015
A) 2007 B) 2015 C) 2010 D) 2021
A) AstraZeneca B) Moderna C) Honeywell D) PhRMA
A) Ultomiris B) Kanuma C) Strensiq D) Soliris
A) David Anderson B) David Brennan C) David Hallal D) Ludwig N. Hantson
A) Influenza B) Lysosomal acid lipase deficiency C) Hypophosphatasia D) Escherichia coli (EHEC)
A) Smithfield, Rhode Island B) Cheshire, Connecticut C) New Haven, Connecticut D) Boston, Massachusetts
A) 1992 B) 2010 C) 2016 D) 2021
A) Steven Squinto B) Ludwig N. Hantson C) David Anderson D) David Hallal |